泽璟制药筹划香港上市 科创板创新药企加速国际化战略布局

Core Points - Suzhou Zejing Biopharmaceutical Co., Ltd. announced on November 15, 2025, that it has approved the issuance of H-shares and plans to list on the Hong Kong Stock Exchange [1] - The purpose of this issuance and listing is to support the company's international strategy and overseas business expansion, enhance brand recognition, and improve overall competitiveness [1] - The company is currently in discussions with relevant intermediaries regarding the details of the issuance and listing, which have not yet been finalized [1] - The specific details, including the proposed share issuance ratio, will require approval from the company's shareholders and regulatory bodies such as the China Securities Regulatory Commission and the Hong Kong Stock Exchange [1]